An effective treatment approach of DPP-IV inhibitor encapsulated polymeric nanoparticles conjugated with anti-CD-4 mAb for type 1 diabetes

References

• Kwon H, Jun H-S, Yang Y, et al. Development of autoreactive diabetogenic T cells in the thymus of NOD mice. J Autoimmun. 2005; 24: 11–23.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell. 2008;133:775–787.
   PubMed Web of Science ®Google Scholar
• You S. CD3-specific antibodies to restore tolerance in autoimmune diabetes. Drug Discov Today Ther Strateg. 2009;6: 33–38.
   Google Scholar
• Danke NA, Koelle DM, Yee C, et al. Autoreactive T cells in healthy individuals. J Immunol. 2004; 172: 5967–5972.
   PubMed Web of Science ®Google Scholar
• Buteau J, Foisy S, Joly E, et al. Glucagon-like peptide 1 induces pancreatic β-cell proliferation via transactivation of the epidermal growth factor receptor. Diabetes. 2003;52: 124–132.
   PubMed Web of Science ®Google Scholar
• Klinger S, Poussin C, Debril M-B, et al. Increasing GLP-1–induced β-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-α and DUSP14. Diabetes. 2008;57:584–593.
   PubMed Web of Science ®Google Scholar
• Liu M-J, Shin S, Li N, et al. Prolonged remission of diabetes by regeneration of β cells in diabetic mice treated with recombinant adenoviral vector expressing glucagon-like peptide-1. Mol Ther. 2007;15:86–93.
   PubMed Web of Science ®Google Scholar
• Kielgast U, Holst JJ, Madsbad S. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function. Diabetes. 2011;60:1599–1607.
   PubMed Web of Science ®Google Scholar
• Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52:741–750.
   PubMed Web of Science ®Google Scholar
• Duttaroy A, Voelker F, Merriam K, et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur J Pharmacol. 2011;650:703–707.
   PubMed Web of Science ®Google Scholar
• Ellis S, Moser EG, Snell-Bergeon JK, et al. Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial. Diabet Med. 2011;28:1176–1181.
   PubMed Web of Science ®Google Scholar
• Narayanan S, Pavithran M, Viswanath A, et al. Sequentially releasing dual-drug-loaded PLGA–casein core/shell nanomedicine: design, synthesis, biocompatibility and pharmacokinetics. Acta Biomaterialia. 2014;10:2112–2124.
   PubMed Web of Science ®Google Scholar
• Beck A. Review of antibody-drug conjugates, methods in molecular biology series: a book edited by Laurent Ducry. MAbs. 2014;6:30–33.
   PubMedGoogle Scholar
• Dubala A, Gupta A, Samanta MK. Combination of monoclonal antibodies and DPP-IV inhibitors in the treatment of type 1 diabetes: a plausible treatment modality? Med Hypotheses. 2014;83:1–5.
   PubMed Web of Science ®Google Scholar
• Murakami H, Kobayashi M, Takeuchi H, et al. Preparation of poly (DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm. 1999;187:143–152.
   PubMed Web of Science ®Google Scholar
• Fonte P, Reis S, Sarmento B. Facts and evidences on the lyophilization of polymeric nanoparticles for drug delivery. J Control Release. 2016;225:75–86.
   PubMed Web of Science ®Google Scholar
• Chung N-O, Lee MK, Lee J. Mechanism of freeze-drying drug nanosuspensions. Int J Pharm. 2012;437:42–50.
   PubMed Web of Science ®Google Scholar
• Williams N, Polli G. The lyophilization of pharmaceuticals: a literature review. PDA J Pharm Sci Technol. 1984;38:48–60.
   Google Scholar
• Siddhartha VT, Pindiprolu SKSS, Chintamaneni PK, et al. RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies. Artif Cells Nanomed Biotechnol. 2017;46:387–397.
   PubMed Web of Science ®Google Scholar
• Sathyamoorthy N, Magharla D, Chintamaneni P, et al. Optimization of paclitaxel loaded poly (ε-caprolactone) nanoparticles using box behnken design. Beni-Suef Univ J Basic Appl Sci. 2017;6;362–373.
   Google Scholar
• Dudhipala N, Janga KY. Lipid nanoparticles of zaleplon for improved oral delivery by Box–Behnken design: optimization, in vitro and in vivo evaluation. Drug Dev Ind Pharm. 2017;43:1205–1214.
   PubMed Web of Science ®Google Scholar
• Dubala A, et al. Bioanalytical method development and validation of sitagliptin phosphate by RP-HPLC and its application to pharmacokinetic study. Int J Pharm Pharm Sci. 2012;4:691–694.
   Google Scholar
• Chourasiya V, Bohrey S, Pandey A. Formulation, optimization, characterization and in-vitro drug release kinetics of atenolol loaded PLGA nanoparticles using 3 3 factorial design for oral delivery. Mat Discov. 2016;5:1–13.
   Google Scholar
• Nobs L, Buchegger F, Gurny R, et al. Surface modification of poly (lactic acid) nanoparticles by covalent attachment of thiol groups by means of three methods. Int J Pharm. 2003;250:327–337.
   PubMed Web of Science ®Google Scholar
• Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys. 1959;82:70–77.
   PubMed Web of Science ®Google Scholar
• Nobs L, Buchegger F, Gurny R, et al. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjugate Chem. 2006;17:139–145.
   PubMed Web of Science ®Google Scholar
• Vijayan P, Kumar SV, Dhanaraj SA, et al. In vitro cytotoxicity and anti-tumor properties of the total alkaloid fraction of unripe fruits of Solanum pseudocapsicum. Pharm Biol. 2002;40:456–460.
   Web of Science ®Google Scholar
• Raju K, Balaraman R. Antidiabetic mechanisms of saponins of Momordica cymbalaria. Pharmacogn Mag. 2008;4:197.
   Web of Science ®Google Scholar